Proof of Mechanism in ELT (PoM)
Primary Purpose
Premature Ejaculation
Status
Completed
Phase
Phase 1
Locations
Italy
Study Type
Interventional
Intervention
GSK958108
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Premature Ejaculation
Eligibility Criteria
Inclusion Criteria:
- Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation
- Baseline Ejaculation Latency time < 3 minutes
- Subjects must agree to use a contraception methods as per protocol
- Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2
- Subject with normal visual acuity (with appropriate correction if needed)
- Subject able to cooperate in all study procedure including the eye examination with use of mydriatics
Exclusion Criteria:
- Erectile dysfunction
- History of migraine
- Current clinically relevant abnormality
- History of psychiatric illness or suicidal attempts or behaviours
- History of any eye disorder or colour blind, excluding myopia and presbyopia
- Cardiac conduction disorder or other clinically significant cardiac disease
- Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests
- Regular consumption of alcohol
- History of sensitivity or intolerance to drugs
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication
- Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication
- Participation in another clinical trial in the previous month
- Exposure to more than four new experimental drugs within the previous 12 months
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
Sites / Locations
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
GSK958108 3 mg
Placebo of GSK958108
Arm Description
Experimental
Placebo
Outcomes
Primary Outcome Measures
Time to achieve ejaculation from the start of masturbation during audio-video erotic stimuli
Secondary Outcome Measures
Safety and tolerability measured as adverse events occurrence, vital signs variations, safety laboratory, eye assessments, ECG and physical examination
Blood concentration of GSK958108 at different timepoints
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00861484
Brief Title
Proof of Mechanism in ELT
Acronym
PoM
Official Title
A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
November 26, 2008 (Actual)
Primary Completion Date
December 11, 2009 (Actual)
Study Completion Date
December 11, 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Ejaculation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GSK958108 3 mg
Arm Type
Experimental
Arm Description
Experimental
Arm Title
Placebo of GSK958108
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
GSK958108
Intervention Description
Coated Tablets 1 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Coated tablets
Primary Outcome Measure Information:
Title
Time to achieve ejaculation from the start of masturbation during audio-video erotic stimuli
Time Frame
50 minutes
Secondary Outcome Measure Information:
Title
Safety and tolerability measured as adverse events occurrence, vital signs variations, safety laboratory, eye assessments, ECG and physical examination
Time Frame
8 weeks
Title
Blood concentration of GSK958108 at different timepoints
Time Frame
From predose to 30 hours post-dose
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation
Baseline Ejaculation Latency time < 3 minutes
Subjects must agree to use a contraception methods as per protocol
Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2
Subject with normal visual acuity (with appropriate correction if needed)
Subject able to cooperate in all study procedure including the eye examination with use of mydriatics
Exclusion Criteria:
Erectile dysfunction
History of migraine
Current clinically relevant abnormality
History of psychiatric illness or suicidal attempts or behaviours
History of any eye disorder or colour blind, excluding myopia and presbyopia
Cardiac conduction disorder or other clinically significant cardiac disease
Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests
Regular consumption of alcohol
History of sensitivity or intolerance to drugs
Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication
Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start
Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication
Participation in another clinical trial in the previous month
Exposure to more than four new experimental drugs within the previous 12 months
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
Unwillingness or inability to follow the procedures outlined in the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Verona
State/Province
Veneto
ZIP/Postal Code
37134
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Links:
URL
https://www.clinicalstudydatarequest.com
Description
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Dataset Specification
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Annotated Case Report Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
111155
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Learn more about this trial
Proof of Mechanism in ELT
We'll reach out to this number within 24 hrs